Translational tool helps ID genetic markers

Disease diagnostics developer Celera is using the InforSense translational research solution to identify genetic markers indicating increased risk of coronary heart disease. The solution allows researchers to integrate internal molecular data sources and public data sources, speeding the marker-identification process.

Coronary heart disease is among the leading causes of death in the U.S., and studies indicate that perhaps half of all myocardial infarction-so-called silent heart attacks, which affect about 200,000 people annually-go unrecognized. Early warning systems for coronary hear disease could have life-saving implications for patients.

The InforSense software provides for the integration and analysis of clinical, patient specimen, and experimental data. It automates aspects of data analysis and molecular annotation.

Celera used the knowledge gained from the identification of the gene variant in KIF6, which predicts coronary heart disease, to build bioinformatics queries and statistical analysis workflows. Such workflows streamline the process of finding genetic markers and promise to speed discovery efforts.

InforSense says it has provided Celera with a solution to support clinical data browsing, automated integration and analysis of enzyme-linked immunoassay, single nucleotide polymorphisms (SNPs), and other experimental proprietary and public data.

- check out the InforSense release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.